Overview

A Phase II Study of Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This study is phase II, open label, clinical trial to determine the efficacy of oregobomab and PLD combination therapy in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer patients who were not suitable for platinum retreatment.
Phase:
Phase 2
Details
Lead Sponsor:
Yonsei University